The bcl-2 gene encodes a protein which inhibits programmed cell death
(apoptosis). This protein was detected by immunohistochemical techniqu
es in 48% of invasive ductal carcinomas of the breast. It was present
in well-differentiated carcinomas with hormonal receptors, and protein
s synthesized under the control of oestrogens: pS2, cathepsin D and ER
D5. In contrast, bcl-2(+) carcinomas are less frequently positive for
p53 and have a Ki67 score under the mean. bcl-2 protects cells against
apoptosis. Accumulation of p53 protein, which is indicative of p53 mu
tation, would have the same effect; however, these two proteins seem i
nversely related, an inverse correlation observed by others in breast
cancer cell lines and in lymphomas. Tumours positive for bcl-2 escape
apoptosis and have worse prognosis but this is not what is found; surv
ival at 5 years, and particularly the absence of recurrence during the
first 5 years after surgery, seem to be associated with bcl-2 positiv
ity. The bcl-2 protein seems only to be an important prognostic factor
in women over 54 years of age. Moreover, p53-bcl-2(+) tumours have a
better response to hormonal therapy than p53-bcl-2- tumours.